No way of stopping leak of deadly new flu, says terror chief

US biosecurity board expert warns against details of H5N1 bird flu getting into wrong hands

Professor Paul Keim says the world is not yet prepared for a strain of the virus
Professor Paul Keim says the world is not yet prepared for a strain of the virus

The bioterrorism expert responsible for censoring scientific research which could lead to the creation of a devastating pandemic has admitted the information "is going to get out" eventually.

Professor Paul Keim, chairman of the US National Science Advisory Board for Biosecurity, controversially recommended that researchers be stopped from publishing the precise mutations needed to transform the H5N1 strain of birdflu virus into a human-transmissible version.

In an exclusive interview with The Independent, he argued it had been necessary to limit the release of the scientific details because of fears that terrorists may use the information to create their own H5N1 virus that could be spread easily between people.

Professor Keim said that it was necessary to slow down the release of scientific information because it was clear that the world is not yet prepared for a strain of highly lethal H5N1 influenza that can be transmitted by coughs and sneezes.

“We recognised that, in the long term certainly, the information is going to get out, and maybe even in the mid term. But if we can restrict it in the short term and motivate governments to start getting busy in terms of building up the flu-defence infrastructure, then we’ve succeeded at a certain level,” he said.

“If we can slow down the release of the specific information that would enable somebody to reconstruct this virus and do something nefarious, even for a while, then that was a good thing.”

By withholding key details of the mutations needed to make an airborne strain of H5N1, this would give time for governments to prepare for and prevent a possible pandemic, he added.

“The infrastructure to stop a pandemic in this area is not there. We just don’t have the capabilities. The very first time we knew that the swine flu virus [coming out of Mexico] was there, it was already in 18 countries. I’m not confident at all that we have the surveillance capability to spot an emerging virus in time to stop it,” he said.

“And even if we did spot it early on, I don’t think we have sufficient vaccines. The vaccines aren’t good enough, and the drugs are not good enough to stop this emerging and being a pandemic.”

Although H5N1 spreads rapidly between birds, it has so far affected only about 600 people worldwide who have had direct contact with infected poultry. However, two teams of researchers have shown independently that it only requires five mutations for H5N1 to become an airborne pathogen for laboratory ferrets, the standard animal model for human influenza.

Professor Keim said that the biosecurity board was asked by the US Government to review the two independent studies because they had already been submitted to the journals Science and Nature. The board had to make a recommendation on whether any or all of the information should be published.

Scientists involved in showing how the H5N1 birdflu virus can be transmitted in the air between ferrets have criticised the biosecurity board’s decision to part-censor their research on the grounds that it would hinder the development of new vaccines and drugs.

However, Professor Keim dismissed the criticism as disingenuous. “The argument that we need this information to make better vaccines and better drugs does not ring true,” he said. “There are lots of ways to make drugs against this virus. The very drugs they were using against this virus were the very same ones used against other flu viruses. The drug-invention problem has nothing to do with having this virus to hand,” he added.

Professor Keim revealed that although he is personally in favour of the research that led to the creation of airborne strains of H5N1, some other members of the board were not convinced. “I’m personally in favour of this research but that opinion is not universal on the board. Some people on the board wanted to stop this research and destroy the virus,” he said.

“I don’t think we need this virus to prove that Tamiflu works against it. And we know that the H5 antigen is not a great antigen for vaccines, we don’t need the virus to tell us that. But there are some experiments that can only be done with the live virus and I’m in favour of keeping the virus for those type of experiments.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in